Clinical Trial Update: Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) [Phase 2, Phase 3]

View source ↗

Summary

A study update on repetitive intramyocardial CD34+ cell therapy for dilated cardiomyopathy and heart failure (REMEDIUM) spanning phase 2 and phase 3, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure

Drugs mentioned

• CD34+ cell therapy (CD34+ cells)

Snippet

Sponsor: University Medical Centre Ljubljana | Conditions: Dilated Cardiomyopathy, Heart Failure | Phase 2, Phase 3 | Status: COMPLETED